Excision BioTherapeutics

A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing. Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical trials after the FDA cleared an investigational new drug application.

Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of infectious disease expert and clinical scientist Sumathi Sivapalasingam, M.D., as Head of Translational Medicine.

Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry development veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing.

Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of gene therapy and rare disease expert, Nicole Paulk, Ph.D., to its Scientific Advisory Board (SAB).

Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of Christine Silverstein as Chief Financial Officer.